106 filings
Page 2 of 6
8-K
jd844sbnz n3
8 Feb 24
Other Events
4:05pm
8-K
to2wt5umudm5z0 0sz8
12 Dec 23
Other Events
4:15pm
8-K/A
zxockdz yb
11 Dec 23
Other Events
6:15am
8-K
s350p03zmjywil
8 Dec 23
Other Events
7:31am
8-K
vua66jm
6 Dec 23
Regulation FD Disclosure
8:13pm
424B5
lhr7 pi41
28 Nov 23
Prospectus supplement for primary offering
6:35pm
EFFECT
3usl qgn5s99nw
28 Nov 23
Notice of effectiveness
12:15am
8-K
dvewadx
27 Nov 23
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability
4:05pm
CORRESP
t2w01ou
27 Nov 23
Correspondence with SEC
12:00am
CORRESP
k906qd
27 Nov 23
Correspondence with SEC
12:00am
CORRESP
zbbgwoh
24 Nov 23
Correspondence with SEC
12:00am
CORRESP
l9cnu0g6
24 Nov 23
Correspondence with SEC
12:00am
FWP
l9m ay067zquj0
17 Nov 23
Free writing prospectus
5:24pm
8-K
2w2bo4l
17 Nov 23
Tharimmune Announces 1-for-25 Reverse Stock Split
4:05pm
8-K
vf9d wg0r
16 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
UPLOAD
4l8bu7k5odnk 5xisiuf
10 Nov 23
Letter from SEC
12:00am
8-K
ksnrppn 0irt44
7 Nov 23
Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
4:10pm